Lantern Pharma Inc.
LTRN
$1.77
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.72M | 1.68M | 1.46M | 1.91M | 1.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.51M | 3.41M | 4.20M | 4.35M | 4.65M |
| Operating Income | -3.51M | -3.41M | -4.20M | -4.35M | -4.65M |
| Income Before Tax | -7.07M | -3.33M | -4.07M | -4.18M | -4.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.07M | -3.33M | -4.07M | -4.18M | -4.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.07M | -3.33M | -4.07M | -4.18M | -4.33M |
| EBIT | -3.51M | -3.41M | -4.20M | -4.35M | -4.65M |
| EBITDA | -3.50M | -3.40M | -4.20M | -4.35M | -4.65M |
| EPS Basic | -0.57 | -0.30 | -0.36 | -0.39 | -0.40 |
| Normalized Basic EPS | -0.36 | -0.18 | -0.22 | -0.24 | -0.25 |
| EPS Diluted | -0.57 | -0.30 | -0.36 | -0.39 | -0.40 |
| Normalized Diluted EPS | -0.36 | -0.18 | -0.22 | -0.24 | -0.25 |
| Average Basic Shares Outstanding | 12.42M | 11.25M | 11.32M | 10.83M | 10.78M |
| Average Diluted Shares Outstanding | 12.42M | 11.25M | 11.32M | 10.83M | 10.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |